Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10017570HBVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30010694HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052490HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052491HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052492HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052493HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052494HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TCGA Plot Options
Drug Information
GeneHTR2B
DrugBank IDDB00320
Drug NameDihydroergotamine
Target IDBE0000393
UniProt IDP41595
Regulation Typeagonist
PubMed IDs11752352; 12970106; 22444161; 23815106
CitationsChen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L: Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. Epub 2003 Aug 11.@@Dahlof C, Maassen Van Den Brink A: Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22.@@Ramirez Rosas MB, Labruijere S, Villalon CM, Maassen Vandenbrink A: Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2.
GroupsApproved; Investigational
Direct ClassificationErgotamines, dihydroergotamines, and derivatives
SMILES[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Pathways
PharmGKBPA164743028
ChEMBLCHEMBL1732